JPS61144573A - サンドイツチイムノアツセイ - Google Patents

サンドイツチイムノアツセイ

Info

Publication number: JPS61144573A
Authority: JP; Japan
Prior art keywords: specific binding; binding substance; antibody; ligand; probe
Prior art date: 1984-12-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP60246122A

Other languages

English (en)

Japanese (ja)

Inventor

フレデリツク、ジエームス、プリマス

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Immunomedics Inc

Original Assignee

Immunomedics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-12-12

Filing date

1985-11-01

Publication date

1986-07-02

1985-11-01 Application filed by Immunomedics Inc filed Critical Immunomedics Inc

1986-07-02 Publication of JPS61144573A publication Critical patent/JPS61144573A/ja

Status Pending legal-status Critical Current

Links

238000003018 immunoassay Methods 0.000 title claims description 21
239000000523 sample Substances 0.000 claims description 75
230000009870 specific binding Effects 0.000 claims description 66
239000000126 substance Substances 0.000 claims description 65
239000003446 ligand Substances 0.000 claims description 51
238000000034 method Methods 0.000 claims description 33
238000012360 testing method Methods 0.000 claims description 32
102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 20
108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 18
239000000427 antigen Substances 0.000 claims description 17
102000036639 antigens Human genes 0.000 claims description 16
108091007433 antigens Proteins 0.000 claims description 16
239000007788 liquid Substances 0.000 claims description 13
238000000926 separation method Methods 0.000 claims description 13
239000012071 phase Substances 0.000 claims description 11
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 10
239000011230 binding agent Substances 0.000 claims description 10
239000003550 marker Substances 0.000 claims description 10
102000004190 Enzymes Human genes 0.000 claims description 9
108090000790 Enzymes Proteins 0.000 claims description 9
238000011534 incubation Methods 0.000 claims description 8
238000001514 detection method Methods 0.000 claims description 7
230000027455 binding Effects 0.000 claims description 6
239000003153 chemical reaction reagent Substances 0.000 claims description 6
239000007791 liquid phase Substances 0.000 claims description 6
108090001008 Avidin Proteins 0.000 claims description 5
229960002685 biotin Drugs 0.000 claims description 5
235000020958 biotin Nutrition 0.000 claims description 5
239000011616 biotin Substances 0.000 claims description 5
230000000295 complement effect Effects 0.000 claims description 5
206010028980 Neoplasm Diseases 0.000 claims description 4
238000011002 quantification Methods 0.000 claims description 4
241000894006 Bacteria Species 0.000 claims description 3
241000700605 Viruses Species 0.000 claims description 3
210000001072 colon Anatomy 0.000 claims description 3
210000001006 meconium Anatomy 0.000 claims description 3
241000894007 species Species 0.000 claims description 2
208000015181 infectious disease Diseases 0.000 claims 4
230000002458 infectious effect Effects 0.000 claims 4
241000233866 Fungi Species 0.000 claims 2
102100035703 Prostatic acid phosphatase Human genes 0.000 claims 2
102000013529 alpha-Fetoproteins Human genes 0.000 claims 2
108010026331 alpha-Fetoproteins Proteins 0.000 claims 2
229960004407 chorionic gonadotrophin Drugs 0.000 claims 2
108010043671 prostatic acid phosphatase Proteins 0.000 claims 2
239000007790 solid phase Substances 0.000 description 13
102000003992 Peroxidases Human genes 0.000 description 11
108040007629 peroxidase activity proteins Proteins 0.000 description 11
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 10
230000002494 anti-cea effect Effects 0.000 description 10
238000003556 assay Methods 0.000 description 9
108010015776 Glucose oxidase Proteins 0.000 description 8
239000004366 Glucose oxidase Substances 0.000 description 8
229940116332 glucose oxidase Drugs 0.000 description 8
235000019420 glucose oxidase Nutrition 0.000 description 8
239000004793 Polystyrene Substances 0.000 description 7
229940088598 enzyme Drugs 0.000 description 7
229920002223 polystyrene Polymers 0.000 description 7
239000000243 solution Substances 0.000 description 7
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 5
241001529936 Murinae Species 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
230000002596 correlated effect Effects 0.000 description 5
230000000694 effects Effects 0.000 description 5
108090000765 processed proteins & peptides Proteins 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
239000007787 solid Substances 0.000 description 4
241000699670 Mus sp. Species 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
241000283707 Capra Species 0.000 description 2
208000001333 Colorectal Neoplasms Diseases 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
230000003302 anti-idiotype Effects 0.000 description 2
CLRSZXHOSMKUIB-UHFFFAOYSA-M benzenediazonium chloride Chemical compound [Cl-].N#[N+]C1=CC=CC=C1 CLRSZXHOSMKUIB-UHFFFAOYSA-M 0.000 description 2
239000000337 buffer salt Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
239000008188 pellet Substances 0.000 description 2
239000000186 progesterone Substances 0.000 description 2
229960003387 progesterone Drugs 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
238000005406 washing Methods 0.000 description 2
LPJXPACOXRZCCP-VIFPVBQESA-N (2s)-2-benzamidopentanedioic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)C1=CC=CC=C1 LPJXPACOXRZCCP-VIFPVBQESA-N 0.000 description 1
JRBJSXQPQWSCCF-UHFFFAOYSA-N 3,3'-Dimethoxybenzidine Chemical compound C1=C(N)C(OC)=CC(C=2C=C(OC)C(N)=CC=2)=C1 JRBJSXQPQWSCCF-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
108020005199 Dehydrogenases Proteins 0.000 description 1
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
206010027457 Metastases to liver Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000012472 biological sample Substances 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
201000010897 colon adenocarcinoma Diseases 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004040 coloring Methods 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
229940028334 follicle stimulating hormone Drugs 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000003292 glue Substances 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
238000002372 labelling Methods 0.000 description 1
230000002366 lipolytic effect Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000005265 lung cell Anatomy 0.000 description 1
244000005700 microbiome Species 0.000 description 1
239000000203 mixture Substances 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
238000006395 oxidase reaction Methods 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
239000007981 phosphate-citrate buffer Substances 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
239000007974 sodium acetate buffer Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
- G01N33/539—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody involving precipitating reagent, e.g. ammonium sulfate
- G01N33/541—Double or second antibody, i.e. precipitating antibody
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
- Y10S436/813—Cancer
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/822—Identified hapten
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/807—Hapten conjugated with peptide or protein

Landscapes

Health & Medical Sciences (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Analytical Chemistry (AREA)
Cell Biology (AREA)
Pathology (AREA)
Food Science & Technology (AREA)
Biotechnology (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Chemical Kinetics & Catalysis (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

JP60246122A 1984-12-12 1985-11-01 サンドイツチイムノアツセイ Pending JPS61144573A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US06/680,730 US4737453A (en)	1984-12-12	1984-12-12	Sandwich immunoassay utilizing a separation specific binding substance
US680730		1984-12-12

Publications (1)

Publication Number	Publication Date
JPS61144573A true JPS61144573A (ja)	1986-07-02

Family

ID=24732276

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP60246122A Pending JPS61144573A (ja)	1984-12-12	1985-11-01	サンドイツチイムノアツセイ

Country Status (6)

Country	Link
US (1)	US4737453A (fr)
EP (1)	EP0188093A3 (fr)
JP (1)	JPS61144573A (fr)
AU (1)	AU5070785A (fr)
CA (1)	CA1254828A (fr)
ZA (1)	ZA859463B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH04501606A (ja) *	1988-11-10	1992-03-19	フアーマシア・ビオセンソル・アクチエボラーグ	センサーユニット及びバイオセンサーシステムにおけるその使用

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE76690T1 (de) *	1985-10-22	1992-06-15	Centocor Inc	Immunometrischer test fuer hochmolekulargewichtiges karzinoembryonisches antigen.
US5501949A (en)	1985-12-10	1996-03-26	Murex Diagnostics Corporation	Particle bound binding component immunoassay
FR2601455B1 (fr) *	1986-07-11	1989-08-04	Stallergenes Lab	Nouveaux reactifs biologiques en phase solide et leur procede d'obtention
US5206136A (en) *	1986-11-19	1993-04-27	Genetic Systems Corporation	Rapid membrane affinity concentration assays
US5206178A (en) *	1986-11-19	1993-04-27	Genetic Systems Corporation	Membrane affinity concentration immunoassay
US4870007A (en) *	1987-12-18	1989-09-26	Eastman Kodak Company	Immobilized biotinylated receptor in test device, kit and method for determining a ligand
US5066479A (en) *	1988-05-31	1991-11-19	The Regents Of The Univ. Of California	Metallacarborane chelates
US5620845A (en) *	1988-06-06	1997-04-15	Ampcor, Inc.	Immunoassay diagnostic kit
DE3834766A1 (de) *	1988-10-12	1990-04-26	Boehringer Mannheim Gmbh	Verfahren zur bestimmung einer spezifisch bindefaehigen substanz
CA2072758A1 (fr) *	1990-09-14	1992-03-15	Kenneth Francis Buechler	Anticorps liant aux complexes de recepteurs de ligands et de ligands et leur utilite dans les tests ligand-recepteur
AU9052491A (en) *	1990-11-19	1992-06-11	University Of Florida	Assay device and method for antibody and antigen detection
ATE225512T1 (de) *	1991-03-20	2002-10-15	Marconi Optical Components Ltd	Abtrennungsverfahren
GB9125204D0 (en) *	1991-11-27	1992-01-29	Marconi Gec Ltd	Analysis
CA2104596A1 (fr) *	1992-01-06	1993-07-07	Dade International Inc.	Reactif immunochimique multi-test et methode d'utilisation
EP0660935B1 (fr) *	1992-08-03	2000-05-24	Gec-Marconi Limited	Detection immunologique au moyen de deux marqueurs detectables
WO1994003807A1 (fr) *	1992-08-03	1994-02-17	Gec-Marconi Limited	Procede de separation
WO1994012878A1 (fr) *	1992-11-27	1994-06-09	Gec-Marconi Limited	Procede de separation
JPH07209299A (ja) *	1994-01-05	1995-08-11	Channa Shalittin	良性及び悪性腫瘍の検出のための新規抗体の使用方法
WO1997006439A1 (fr)	1995-08-09	1997-02-20	Quidel Corporation	Lame d'epreuve et methode d'analyse en flux lateral en une seule etape
FR2742662B1 (fr) *	1995-12-21	1998-01-23	Centre Nat Rech Scient	Anticorps anti-idiotypiques du facteur de croissance endotheliale vasculaire et leur utilisation comme medicaments
US5888757A (en) *	1996-05-03	1999-03-30	Millennium Pharmaceuticals, Inc.	Cell wall assay
US5795784A (en)	1996-09-19	1998-08-18	Abbott Laboratories	Method of performing a process for determining an item of interest in a sample
US5856194A (en)	1996-09-19	1999-01-05	Abbott Laboratories	Method for determination of item of interest in a sample
EP0983509B1 (fr) *	1997-05-14	2005-08-17	Biosite Diagnostics Inc.	Evaluation rapide d'une proportion de molecules biologiques
AU9498098A (en)	1997-09-22	1999-04-12	Chiron Corporation	Buffers for stabilizing antigens
DE69837155T2 (de) *	1997-09-22	2007-06-21	Novartis Vaccines and Diagnostics, Inc., Emeryville	Verfahren zum nachweiss von antikörpern in einer probe
US6242246B1 (en) *	1997-12-15	2001-06-05	Somalogic, Inc.	Nucleic acid ligand diagnostic Biochip
US20070166741A1 (en)	1998-12-14	2007-07-19	Somalogic, Incorporated	Multiplexed analyses of test samples
US20060057573A1 (en) *	2002-02-15	2006-03-16	Somalogic, Inc	Methods and reagents for detecting target binding by nucleic acid ligands
US7138103B2 (en) *	1998-06-22	2006-11-21	Immunomedics, Inc.	Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6962702B2 (en) *	1998-06-22	2005-11-08	Immunomedics Inc.	Production and use of novel peptide-based agents for use with bi-specific antibodies
US7387772B1 (en)	1999-06-22	2008-06-17	Immunimedics, Inc.	Chimeric, human and humanized anti-CSAP monoclonal antibodies
US7833528B2 (en) *	1998-06-22	2010-11-16	Immunomedics, Inc.	Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
US7405320B2 (en)	1998-06-22	2008-07-29	Immunomedics, Inc.	Therapeutic and diagnostic conjugates for use with multispecific antibodies
PL204235B1 (pl) *	1999-01-29	2009-12-31	Roche Diagnostics Gmbh	Sposób wykrywania natywnego N-końcowego proBNP, zastosowanie tego sposobu, zastosowanie zrekombinowanego N-końcowego proBNP, przeciwciała przeciw zrekombinowanemu N-końcowemu proBNP, linie komórkowe i sposoby wytwarzania przeciwciał poliklonalnych i monoklonalnych
CA2328356A1 (fr) *	1999-12-22	2001-06-22	Itty Atcravi	Vehicules recreatifs
US7645743B2 (en) *	1999-12-22	2010-01-12	Altermune, Llc	Chemically programmable immunity
JP4667874B2 (ja) *	2002-12-26	2011-04-13	メソスケールテクノロジーズエルエルシー	バイオマーカーを抽出するための方法、組成物およびキット
US20050069958A1 (en) *	2003-09-26	2005-03-31	Mills Rhonda A.	Method for simultaneous evaluation of a sample containing a cellular target and a soluble analyte
US20060024744A1 (en) *	2004-07-28	2006-02-02	Mills Rhonda A	Methods for substantially simultaneous evaluation of a sample containing a cellular target and a soluble analyte
US20060046310A1 (en) *	2004-08-25	2006-03-02	Zong-Li Xia	Amplification method for solid phase immunoassays
CA2634987C (fr) *	2006-01-17	2017-01-03	Somalogic, Inc.	Analyses multiplexees d'echantillons test
US7947447B2 (en)	2007-01-16	2011-05-24	Somalogic, Inc.	Method for generating aptamers with improved off-rates
US7964356B2 (en) *	2007-01-16	2011-06-21	Somalogic, Inc.	Method for generating aptamers with improved off-rates
US20110136099A1 (en)	2007-01-16	2011-06-09	Somalogic, Inc.	Multiplexed Analyses of Test Samples
US7855054B2 (en) *	2007-01-16	2010-12-21	Somalogic, Inc.	Multiplexed analyses of test samples
US8975026B2 (en)	2007-01-16	2015-03-10	Somalogic, Inc.	Method for generating aptamers with improved off-rates
JP5081930B2 (ja) *	2007-03-08	2012-11-28	エフ．ホフマン−ラロシュアーゲー	心不全の評価におけるｓｌｉｍ−１の使用
US8906700B2 (en)	2007-11-06	2014-12-09	Ambergen, Inc.	Methods and compositions for phototransfer
US8703416B2 (en)	2008-07-17	2014-04-22	Somalogic, Inc.	Method for purification and identification of sperm cells
CN102459298A (zh)	2009-05-05	2012-05-16	阿尔特姆恩科技责任有限公司	化学可编程免疫
WO2011109642A1 (fr)	2010-03-03	2011-09-09	Somalogic, Inc.	Aptamères pouvant se lier à 4-1bb et utilisation associée dans le traitement de maladies et de troubles
JP5901610B2 (ja)	2010-04-12	2016-04-13	ソマロジック・インコーポレーテッド	５位修飾ピリミジンとその使用
ES2636483T3 (es) *	2012-02-21	2017-10-05	Laboratory Corporation Of America Holdings	Métodos y sistemas para la amplificación de señal de bioensayos
JP6587934B2 (ja)	2012-03-28	2019-10-09	ソマロジック・インコーポレーテッド	Ｐｄｇｆおよびｖｅｇｆ結合アプタマー、および、ｐｄｇｆおよびｖｅｇｆが介在する病気の治療へのそれらの使用
EP3044334B1 (fr)	2013-09-09	2020-08-12	Somalogic, Inc.	Aptamères de pdgf et vegf présentant une stabilité améliorée et leur utilisation dans le traitement de maladies et de troubles médiés par pdgf et vegf

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL7501215A (nl) *	1975-02-01	1976-08-03	Akzo Nv	Methode voor het aantonen en bepalen van een antigeen of antilichaam.
US4098876A (en) *	1976-10-26	1978-07-04	Corning Glass Works	Reverse sandwich immunoassay
US4134792A (en) *	1976-12-06	1979-01-16	Miles Laboratories, Inc.	Specific binding assay with an enzyme modulator as a labeling substance
US4271140A (en) *	1978-01-23	1981-06-02	Baxter Travenol Laboratories, Inc.	Method and composition for double receptor, specific binding assays
JPS5510590A (en) *	1978-05-04	1980-01-25	Wellcome Found	Enzyme immunity quantity analysis
US4189464A (en) *	1978-05-05	1980-02-19	Institute For Cancer Research	Hepatitis B testing reagent and method
US4230683A (en) *	1978-08-09	1980-10-28	Abbott Laboratories	Hapten conjugated antibody for antibody or antigen detection
US4371515A (en) *	1978-12-26	1983-02-01	E-Y Laboratories, Inc.	Method for forming an isolated lectin-immunological conjugate
US4289747A (en) *	1978-12-26	1981-09-15	E-Y Laboratories, Inc.	Immunological determination using lectin
GB2084317B (en) *	1980-09-30	1984-01-18	Erba Farmitalia	Antigen-linked competitive enzymeimmunoassay
GB2098730B (en) *	1981-04-21	1985-02-06	Welsh Nat School Med	Immunolocalisation
US4478946A (en) *	1981-07-02	1984-10-23	South African Inventions Development Corporation	Carrier bound immunosorbent
US4471058A (en) *	1982-07-26	1984-09-11	Board Of Trustees Operating Michigan State University	Method for the detection and/or determination of a polyvalent antigen using at least two different monoclonal antibodies
EP0105714B1 (fr) *	1982-09-29	1988-07-27	Serono Diagnostics Limited	Immunoessai pour antigènes
US4496654A (en) *	1983-04-08	1985-01-29	Quidel	Detection of HCG with solid phase support having avidin coating
FR2549230B1 (fr) *	1983-06-14	1986-04-11	Bio Merieux	Procede de detection d'un oligomere dans un milieu liquide contenant des monomeres correspondants, dispositif pour la mise en oeuvre de ce procede et application notamment a la recherche d'allergenes

1984
- 1984-12-12 US US06/680,730 patent/US4737453A/en not_active Expired - Fee Related
1985
- 1985-11-01 JP JP60246122A patent/JPS61144573A/ja active Pending
- 1985-11-21 CA CA000495894A patent/CA1254828A/fr not_active Expired
- 1985-12-03 AU AU50707/85A patent/AU5070785A/en not_active Abandoned
- 1985-12-11 ZA ZA859463A patent/ZA859463B/xx unknown
- 1985-12-12 EP EP85309043A patent/EP0188093A3/fr not_active Withdrawn

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH04501606A (ja) *	1988-11-10	1992-03-19	フアーマシア・ビオセンソル・アクチエボラーグ	センサーユニット及びバイオセンサーシステムにおけるその使用

Also Published As

Publication number	Publication date
US4737453A (en)	1988-04-12
EP0188093A2 (fr)	1986-07-23
ZA859463B (en)	1986-09-24
EP0188093A3 (fr)	1987-09-30
CA1254828A (fr)	1989-05-30
AU5070785A (en)	1986-06-19

Publication	Publication Date	Title
JPS61144573A (ja)	1986-07-02	サンドイツチイムノアツセイ
US5011771A (en)	1991-04-30	Multiepitopic immunometric assay
US4886761A (en)	1989-12-12	Polysilicon binding assay support and methods
US4606855A (en)	1986-08-19	Monoclonal antibody to digoxin
EP0158973B1 (fr)	1990-09-26	Essai immunométrique multisite
JPH0421818B2 (fr)	1992-04-14
JPS62284262A (ja)	1987-12-10	イムノアツセイ方法
CA2008360A1 (fr)	1990-07-23	Essai immunologique pour le diagnostic de l'infarctus du myocarde
JPH06102037B2 (ja)	1994-12-14	抗体、製法と用途
JPH0239747B2 (fr)	1990-09-06
JPH0823560B2 (ja)	1996-03-06	免疫的に結合可能の物質の測定法及び診断剤
EP0166623A2 (fr)	1986-01-02	Test-sandwich à anticorps lectine
US4670383A (en)	1987-06-02	Immune-chemical measurement process for haptens and proteins
JPH02238000A (ja)	1990-09-20	がん胎児性抗原の精製法
CA2008304C (fr)	2001-03-27	Dosage de la phosphatase alcaline des os
EP0124366B1 (fr)	1991-10-30	Méthode pour la détermination des ligands biologiques
US4272504A (en)	1981-06-09	Antibody adsorbed support method for carcinoembryonic antigen assay
US5009997A (en)	1991-04-23	Two site cross-reaction immunometric sandwich assay method
JPS60500427A (ja)	1985-03-28	特異性ｃｅａファミリ−抗原、それに対し特異性の抗体およびそれらの使用方法
US5009996A (en)	1991-04-23	Two site cross-reaction immunometric sandwich assay method
JPH04507285A (ja)	1992-12-17	抗イディオトープ免疫検定法
JPS63501982A (ja)	1988-08-04	クレアチンキナ−ゼｍｂ定量方法
EP0109078B1 (fr)	1988-05-04	Essai immunochimique de la gonadotropine chorionique humaine et son réactif
EP0188608A1 (fr)	1986-07-30	Methode d'essai immunometrique du type a sandwich, par reaction croisee a deux sites avec enzymes marquees
JP2651438B2 (ja)	1997-09-10	酵素標識抗体感作ラテックス及びそれを用いた酵素免疫測定法

JPS61144573A - サンドイツチイムノアツセイ - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=24732276

Family Applications (1)

Country Status (6)

Cited By (1)

Families Citing this family (56)

Family Cites Families (16)

Cited By (1)

Also Published As

Similar Documents